Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper

Juliana C Kwok1, Des R Richardson

  • 1The Heart Research Institute, the Iron Metabolism and Chelation Group, Sydney, New South Wales, Australia.

Molecular Pharmacology
|September 19, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The isoflavone metabolites, O-desmethylangolensin and (S)-equol, relax isolated arteries ex vivo and decrease arterial blood pressure in vivo.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

Implementing the design cues of dissociation dynamics and transmetalation in gallium(iii) complexes to promote the anti-proliferative activity of ligands targeting intracellular iron(ii) trafficking.

Chemical science·2026
Same author

Leading artificial intelligence-driven drug discovery platforms: 2025 landscape and global outlook.

Pharmacological reviews·2025
Same author

Artificial intelligence-assisted drug discovery in 2025: Faster, but is it better? The robots are coming, look out!

Pharmacological reviews·2025
Same author

Thiosemicarbazones down-regulate N-Myc expression in neuroblastoma cells via transcriptional and post-translational mechanisms.

Pharmacological research·2025
Same author

Metal-based antibody, nanobody, and peptide conjugates: Potential for breast cancer therapy.

Pharmacological reviews·2025

Anthracyclines like doxorubicin disrupt cellular iron metabolism by interfering with iron-regulatory proteins (IRPs). This interaction, not free radicals, impacts both cancer and heart cells, offering new therapeutic strategies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiology

Background:

  • Anthracyclines are vital chemotherapy drugs but cause heart toxicity due to iron interactions.
  • Understanding anthracycline-iron metabolism in heart and tumor cells is key to improving therapy.
  • Iron-regulatory proteins (IRPs) control cellular iron via mRNA binding.

Purpose of the Study:

  • To investigate how anthracyclines, specifically doxorubicin (DOX), affect iron metabolism in tumor and heart cells.
  • To elucidate the mechanism behind DOX-induced interference with iron-regulatory proteins (IRPs).

Main Methods:

  • Assessed the effect of DOX and its metabolite doxorubicinol on IRP-RNA binding activity.
  • Utilized free radical scavengers to test the role of oxidative stress.

Related Experiment Videos

  • Examined the impact of anthracycline-metal complexes (Fe, Cu) on IRP activity.
  • Investigated the effect of anthracyclines on IRP response to iron depletion by chelators.

    • Main Results:

    • Doxorubicin (DOX) interferes with IRP-RNA binding in both tumor and heart cells.
    • DOX's effect on IRPs is not mediated by free radical production.
    • Anthracycline-metal complexes, not free drug or metabolite, reduce IRP-RNA binding.
    • Anthracyclines inhibit IRPs' response to intracellular iron depletion.

    Conclusions:

    • Anthracycline-induced myocardial toxicity may stem from altered iron metabolism via IRP interference.
    • Combining chelators with anthracyclines could offer novel cancer treatment strategies.
    • DOX impacts iron metabolism similarly in neoplastic and cardiac cells, highlighting a shared mechanism.